IL1B and neoplasm: In fact, the molecular mediators and intracellular pathways responsible for IL-1β production in cancer cells are still poorly defined, and their identification will likely provide additional therapeutic targets to counteract the tumor cell-intrinsic contribution to disease progression by IL-1β signaling.